Post COVID-19 vaccination Guillain-Barre syndrome: three cases

References

• Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, van Doorn PA, Dourado ME, Hughes RA, Islam B, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–5. doi:10.1038/s41582-019-0250-9.
   PubMed Web of Science ®Google Scholar
• Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001;14(5):605–13. doi:10.1097/00019052-200110000-00009.
   PubMed Web of Science ®Google Scholar
• Abolmaali M, Heidari M, Zeinali M, Moghaddam P, Ghamsari MR, Makiani MJ, Mirzaasgari Z. Guillain–barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series. J Clin Neurosci. 2021;83:119–22. doi:10.1016/j.jocn.2020.11.013.
   PubMed Web of Science ®Google Scholar
• Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2). doi:10.7759/cureus.13426.
   Web of Science ®Google Scholar
• Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96(22):1052–54. doi:10.1212/WNL.0000000000011881.
   PubMed Web of Science ®Google Scholar
• Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, Mangat HS. Guillain-Barré syndrome following ChAdox1-S/nCoV-19 vaccine. Ann Neurol. 2021;90(2):312–14. doi:10.1002/ana.26143.
   PubMed Web of Science ®Google Scholar
• Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, Evans JR. Guillain–barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90(2):315–18. doi:10.1002/ana.26144.
   PubMed Web of Science ®Google Scholar
• Karimi N, Boostani R, Fatehi F, Panahi A, Okhovat AA, Ziaadini B, Basiri K, Abdi S, Sinaei F, Rezaei M, et al. Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci. 12(5):703–10. doi:10.32598/bcn.2021.3565.1.
   PubMed Web of Science ®Google Scholar
• Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388(10045):717–27. doi:10.1016/S0140-6736(16)00339-1.
   PubMed Web of Science ®Google Scholar
• Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and guillain-barre syndrome. Drug Safety. 2009;32(4):309–23. doi:10.2165/00002018-200932040-00005.
   PubMed Web of Science ®Google Scholar
• Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain–barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82. doi:10.1038/nrneurol.2014.121.
   PubMed Web of Science ®Google Scholar
• Jacobs B, Rothbarth P, Van der Meché F, Herbrink P, Schmitz P, De Klerk M, van Doorn PA. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–15. doi:10.1212/WNL.51.4.1110.
   PubMed Web of Science ®Google Scholar
• Bardage C, Persson I, Örtqvist Å, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Bmj. 2011;343(oct12 2):d5956. doi:10.1136/bmj.d5956.
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–39. doi:10.1016/S0140-6736(16)00562-6.
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-Barre syndrome following vaccination in the national influenza immunization program, united states, 1976–19771. Am J Epidemiol. 1979;110(2):105–23. doi:10.1093/oxfordjournals.aje.a112795.
   PubMed Web of Science ®Google Scholar
• Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdox1. BMJ Case Rep CP. 2021;14(4):e242956. doi:10.1136/bcr-2021-242956.
   PubMedGoogle Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97. doi:10.1016/S0140-6736(20)31866-3.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951–60. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep. 2021;14(7). doi:10.1136/bcr-2021-244125.
   Google Scholar
• Oo WM, Giri P, De Souza A. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link? J Neuroimmunol. 2021;360:577719. doi:10.1016/j.jneuroim.2021.577719.
   PubMed Web of Science ®Google Scholar
• James J, Jose J, Gafoor VA, Smita B, Balaram N. Guillain‐barré syndrome following ChAdox1 nCov‐19 COVID‐19 vaccination: A case series. Neurol Clin Neurosci. 2021;9(5):402–05. doi:10.1111/ncn3.12537.
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, Feasby TE, Quaskey SA. Motor conduction studies in guillain-barré syndrome: description and prognostic value. Ann Neurol. 1988;23(4):354–59. doi:10.1002/ana.410230407.
   PubMed Web of Science ®Google Scholar
• Akbayram S, Doğan M, Akgün C, Peker E, Sayιn R, Aktar F, Bektaş MS, Çaksen H. Clinical features and prognosis with Guillain-Barré syndrome. Ann Indian Acad Neurol. 2011;14(2):98. doi:10.4103/0972-2327.82793.
   PubMed Web of Science ®Google Scholar
• Vadalà M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? Epma J. 2017;8(3):295–311. doi:10.1007/s13167-017-0101-y.
   PubMed Web of Science ®Google Scholar